This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
TransMedics posts 200% EPS surge and 32% revenue growth in Q4, tops estimates and guides for up to 25% sales growth in 2026.
ANGONegative Net Change ISRGNegative Net Change PACBNegative Net Change TMDXPositive Net Change
earnings medical medical-devices
Alcon's Q4 Earnings Miss Estimates, Stock Falls, Revenues Rise Y/Y
by Zacks Equity Research
ALC's Q4 EPS and revenues lag estimates, sending shares down 3%, even as sales increase 9% and 2026 guidance targets up to 7% growth.
ISRGNegative Net Change ALGNNegative Net Change CAHPositive Net Change ALCNegative Net Change
earnings medical medical-devices
BD Launches Urine Complete Cup Kit for Smarter Testing & Accuracy
by Zacks Equity Research
BDX launches a three-tube urine collection kit to expand testing from one sample, aiming to boost lab efficiency and reduce contamination risks.
BDXPositive Net Change ISRGNegative Net Change CAHPositive Net Change VCYTNegative Net Change
medical medical-devices
Will Medline's Q4 Earnings Validate Its Prime Vendor Growth Strategy?
by Zacks Equity Research
MDLN is set to report first earnings as a public company, with Prime Vendor growth and brand mix in focus ahead of Q4 results.
MCKPositive Net Change COOPositive Net Change STAANegative Net Change MDLNNegative Net Change
medical medical-devices
Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
by Zacks Equity Research
HIMS reports an earnings beat and strong revenue growth in fourth-quarter 2025, but margin pressure and a softer outlook clouded the quarterly performance.
CAHPositive Net Change MCKPositive Net Change HIMSPositive Net Change GEHCNegative Net Change
earnings medical medical-devices
The Zacks Analyst Blog Highlights Oracle, Intuitive Surgical, Analog Devices and Moving iMage Technologies
by Zacks Equity Research
Oracle, Intuitive Surgical and Analog Devices lead fresh research as cloud growth, robotic momentum and AI tailwinds battle margin and tariff risks.
ADINegative Net Change ISRGNegative Net Change ORCLPositive Net Change MITQNegative Net Change
business-services computers medical-devices semiconductor
Zacks Industry Outlook Highlights Intuitive Surgical, Edwards Lifesciences and Electromed
by Zacks Equity Research
Intuitive Surgical, Edwards and Electromed tap GenAI tailwinds as AI healthcare spending surges, despite industry under performance.
ISRGNegative Net Change EWPositive Net Change ELMDPositive Net Change
medical-devices
BrightSpring to Post Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
BTSG is set to report Q4 earnings with strong pharmacy growth, steady provider gains and improving margins.
MCKPositive Net Change COOPositive Net Change STAANegative Net Change BTSGPositive Net Change
medical medical-devices
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down
by Zacks Equity Research
Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.
ISRGNegative Net Change ALGNNegative Net Change CAHPositive Net Change MYGNPositive Net Change
earnings medical medical-devices
Top Research Reports for Oracle, Intuitive Surgical & Analog Devices
by Mark Vickery
Oracle faces cloud competition and earnings volatility, yet AI-driven infrastructure growth and strong cash flow aim to power its next phase.
ADINegative Net Change COFNegative Net Change ISRGNegative Net Change ALLNegative Net Change ORCLPositive Net Change CDNSPositive Net Change MITQNegative Net Change
business-services computers medical-devices semiconductor